Sanofi (SNY)
(Delayed Data from NSDQ)
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $51.22 +0.02 (0.04%) 5:12 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
Sanofi (SNY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$62.88 | $67.00 | $55.00 | 24.69% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Sanofi comes to $62.88. The forecasts range from a low of $55.00 to a high of $67.00. The average price target represents an increase of 24.69% from the last closing price of $50.43.
Analyst Price Targets (4 )
Broker Rating
Sanofi currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, nine are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SNY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.67 | 1.67 | 1.67 | 1.62 | 1.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | Berenberg Bank | Luisa Hector | Strong Buy | Strong Buy |
5/28/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
4/22/2024 | UBS | Andrew Whitney | Strong Buy | Strong Buy |
4/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/4/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Steve M Scala | Hold | Hold |
2/8/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
11/22/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 12 |
Average Target Price | $62.88 |
LT Growth Rate | 7.80% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 186 of 252 |
Current Quarter EPS Est: | 0.88 |